NEW TREATMENTS FOR OBESITY: DOUBLE AGONIST TWO GIP/ GLP-1 RECEPTORS – TIRZEPATIDE

• DOI: https://doi.org/10.22533/at.ed.1594122423011

• Palavras-chave: Tirzepatide, Obesity, Pharmacological Treatment.

• Keywords: Tirzepatide, Obesity, Pharmacological Treatment.

• Abstract:

  Goal: This study seeks to validate the mechanisms of action, the clinical effectiveness and the safety of Tirzepatide as a new therapeutic option for the treatment of obesity. Methodology: Review of bibliographic literature developed from September to November 2023. The research was carried out in the PubMed Central database with a search strategy: (Tirzepatide) AND (Obesity). It was found a total of 156 articles and selected, after application of criteria of inclusion and exclusion, 19 articles were included in the study. Discussion: Obesity is a very prevalent pathology in the world population, which induces various metabolic alterations capable of affecting quality and life expectancy. Among the research for more effective pharmacological treatments, Tirzepatide has stood out as a promising therapeutic option, with a significant reduction in body weight. This drug is a dual agonist of the GIP/GLP-1 receptor, approved for DM2 therapy by the FDA in May 2022. The different studies analyzed demonstrate effects such as improved glycemic control, reduction of HbA1c levels, reduction of triglyceride levels, Best blood pressure and insulin values in the world. Also, because it has greater activity as the GIP receptor when compared to GLP-1, it has better effects in controlling glucose and body weight. Final considerations: Tirzepatide demonstrated clinical efficacy in weight loss and improvement of various markers. The current studies also clarify their mechanism of action and safety, meanwhile, to the majority of the population as carriers of DM2. Logo, it is necessary to develop research that seeks to understand the use of this medication in other patient profiles, not necessarily type 2 diabetics.